The definitive, world-renowned summit dedicated to providing comprehensive insight into the full end-to-end pharmaceutical value chain for CAR-TCR therapies in liquid and solid tumor indications.

The CAR-TCR Summit remains at the forefront of the industry bringing you never-seen-before data from the movers and shakers in CAR and TCR therapy development.

Dedicated to discussing the next generation candidates beyond CD19, from solid tumor indications to autoimmune disorders, this meeting provides an in depth breakdown of the current strategies to optimize the durability, persistence and targeting of approved and novel therapies to reduce relapse rates and overcome toxicity.

At the premier, end-to-end summit focused on early research through to commercialization, join the experts to discuss how to streamline process development and logistics supply chains for affordable and accessible CAR-TCR therapeutics.

Take advantage of the unrivalled networking opportunities as we bring together over 1000 industry leaders developing CAR-TCR based therapies from across pharma, biotech, regulatory bodies, academia, solution and service providers.

Here’s a snapshot of the 140+ world class speaker faculty:

• James Noble, Chief Executive Officer, Adaptimmune
• Barbra Sasu, Chief Scientific Officer, Allogene
• Chris Haqq, Chief Scientific Officer, Atara Biotherapeutics
• Elsy Boglioli, Chief Operating Officer, Cellectis
• Jean-Pierre Latere, Chief Operations Officer, Celyad
• Katherine Szarama, Evidence Development Division, Coverage & Analysis Group, Center for Clinical Standards and Quality, Centers for Medicare & Medicaid Services
• Cheng Liu, Chief Executive Officer, Eureka Inc.
• Jason Krentz, Chief Technology Officer, Tmunity Therapeutics
• Thomas Andresen, Chief Scientific Officer, Torque Therapeutics
• Matthew Spear, Chief Medical Officer, Poseida Therapeutics

Download the event guide for the full details of the speaker line-up, agenda and discounts available.